Search
Levobetaxolol
go.drugbank.com/drugs/DB09351ApprovedIt was marketed as a 0.5% ophthalmic solution of levobetaxolol hydrochloride under the trade name Betaxon but has been discontinued. … Levobetaxolol is a beta-blocker used to lower the pressure in the eye to treat conditions such as glaucoma.
Kaolin
go.drugbank.com/drugs/DB01575ApprovedKaolin is a layered silicate mineral. Kaolin is used in ceramics, medicine, coated paper, as a food additive, in toothpaste, as a light diffusing material in white incandescent light bulbs, and in cosmetics. Until the early 1990s it was ...
Mixtures: No More Products, NEO ASTAFelbamate
go.drugbank.com/drugs/DB00949ApprovedAlternatively, it is used to treat partial and generalized seizures associated with Lennox-Gastaut syndrome in children. It has a weak inhibitory effect on GABA receptor binding sites. … In particular, in the adult patient population, it can be employed to treat partial seizures (with and without generalization).
Ixazomib
go.drugbank.com/drugs/DB09570ApprovedInvestigational[A264329] Ixazomib was approved by the FDA on November 20, 2015, making it the first oral proteasome inhibitor approved in the US. … [A264319] It was later approved by Health Canada on August 3, 2016,[L51239] and by the EMA on November 21, 2016.
Idelalisib
go.drugbank.com/drugs/DB09054ApprovedInvestigationalBy inhibiting this enzyme, idelalisib induces apoptosis of malignant cells and inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and … More specifically, idelalisib targets P110δ, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K.
Retapamulin
go.drugbank.com/drugs/DB01256ApprovedRetapamulin, marketed by GlaxoSmithKline as the ointment Altabax, is an antibiotic for skin infections like impetigo. It was approved by the FDA in April 2007.
Pralidoxime
go.drugbank.com/drugs/DB00733ApprovedInvestigationalVet approvedIf given within 24 hours,after organophosphate exposure, pralidoxime reactivates the enzyme cholinesterase by cleaving the phosphate-ester bond formed between the organophosphate and acetylcholinesterase … Pralidoxime is an antidote to organophosphate pesticides and chemicals.
Levodopa
go.drugbank.com/drugs/DB01235ApprovedInvestigationalThe first developed drug product that was approved by the FDA was a levodopa and carbidopa combined product called Sinemet that was approved on May 2, 1975[A177781,L6133]. … Levodopa is a prodrug of dopamine that is administered to patients with Parkinson's due to its ability to cross the blood-brain barrier[Label].
Mixtures: LEVOCAENT-NX 100/25/200, LEVOCAENT-NX 100/25/200Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeAbiraterone
go.drugbank.com/drugs/DB05812ApprovedInvestigational[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April,[A260880] July,[L47745] and September 2011,[A260880] respectively. … [L54773,L54768] As abiraterone has poor oral bioavailability and is susceptible to hydrolysis by esterases, abiraterone acetate was developed as an orally bioavailable prodrug with enhanced stability
Chlorpromazine
go.drugbank.com/drugs/DB00477ApprovedInvestigationalVet approvedLike the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors.
Synonyms: 3-(2-chloro-10H-phenothiazin-10-yl)-N,N-dimethyl-1-propanamine, 3-(2-chlorophenothiazin-10-yl)-N,N-dimethyl-propan-1-amineCategories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome